Netris Pharma reported positive Phase Ib data for NP-137, a first-in-class inhibitor of netrin-1, targeting chemotherapy resistance in pancreatic cancer. The company’s update centers on the hypothesis that netrin-1 signaling contributes to the resistance biology that limits benefit from standard regimens. The trial results indicate NP-137 can alleviate resistance to chemotherapy in this setting, supporting further development in a disease where resistance mechanisms are a persistent clinical barrier. Netris framed the data as a potential step toward improving treatment efficacy in pancreatic ductal adenocarcinoma. The announcement places netrin-1 inhibition into the broader pancreatic cancer strategy landscape increasingly focused on overcoming microenvironment- and pathway-driven resistance, complementing RAS- and immune-adjacent approaches. With pancreatic outcomes still dominated by late-stage resistance, the emerging NP-137 signal increases the number of actionable mechanisms now being tested in clinically relevant trial populations.